Director, CLL Center & Institute Physician; Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology Dana-Farber Cancer Institute; Harvard Medical School Boston, Massachusetts
Learning Objectives:
Explain the genetic characteristics of CLL/SLL, including 17p deletions, and how gene mutation status affects patient outcomes in response to targeted therapies
valuate the mechanism of action, safety/efficacy data, and potential drug-drug interactions associated with major emerging agents, including Anti CD-20 mABs, BCL-2 inhibitors, and BTK inhibitors